Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs Markets July 20, 2022 [ad_1] NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. at this time introduced it has…
